Who are Xalatan®/DE-130A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Preserved Bimatoprost 0.01%, preservative free tafluprost 0.0015%, Bimatoprost 0.03% solution, Co-Latanoprost, Tafluprost 15µg/ml, travoprost 0.004% (drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xalatan-de-130a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Xalatan®/DE-130A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xalatan®/DE-130A (Xalatan®/DE-130A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: prostaglandin analogue. Area: Ophthalmology.

phase 3 prostaglandin analogue FP receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Xalatan®/DE-130A (Xalatan®/DE-130A) — Santen SAS. Xalatan is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Xalatan®/DE-130A TARGET	Xalatan®/DE-130A	Santen SAS	phase 3	prostaglandin analogue	FP receptor
Preserved Bimatoprost 0.01%	Preserved Bimatoprost 0.01%	Universitaire Ziekenhuizen KU Leuven	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
preservative free tafluprost 0.0015%	preservative free tafluprost 0.0015%	Tun Hussein Onn National Eye Hospital	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Bimatoprost 0.03% solution	Bimatoprost 0.03% solution	Ahmed Hassan Nouh MD	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Co-Latanoprost	Co-Latanoprost	Dr. David Yan	marketed	Prostaglandin analog combination	FP receptor (prostaglandin F receptor)
Tafluprost 15µg/ml	Tafluprost 15µg/ml	Ordination Dr. Hommer	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
travoprost 0.004% (drug)	travoprost 0.004% (drug)	University Hospital, Basel, Switzerland	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (prostaglandin analogue class)

Santen SAS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xalatan®/DE-130A — Competitive Intelligence Brief. https://druglandscape.com/ci/xalatan-de-130a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing